This study focuses on *multiple myeloma*, a type of blood cancer. It's for adults whose cancer has either returned or isn't responding to current treatments. The study tests a drug called **belantamab mafodotin**, which is combined with standard cancer treatments to see if it can fight cancer effectively with fewer side effects, especially on the eyes.

Participants must be 18 or older and have a confirmed diagnosis of multiple myeloma, having tried 1-2 previous treatments. Those with certain health conditions, like active infections or heart problems, cannot participate. The study involves different arms (groups) with specific criteria for each, like prior treatments.

• Participants may need to stop wearing contact lenses during treatment.
• There are strict rules about avoiding pregnancy during the study.
• People with certain health issues or treatment histories are not eligible.